Alnylam Pharmaceuticals, Inc. (ALNY:NASDAQ) closed at $234.63 on October 19, 2026, up 1.21% on the day. The stock trades 52.7% below its 52-week high of $495.55 and 18.6% above its 52-week low of $197.81. Over the past year, it lost 51.9%. Alnylam Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +2.12% | -5.57% | -14.98% | -25.44% | -51.87% |
In 252 trading sessions since October 16, 2025, ALNY closed higher on 126 days (50%). Its best day was September 2, 2026 (+8.65%) and its worst was July 30, 2026 (-28.31%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto...
Find more stocks like ALNY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.